Get the Stockscreener App
17.04
5.25%
0.85
Syndax Pharmaceuticals Inc stock is traded at $17.04, with a volume of 2.95M.
It is up +5.25% in the last 24 hours and up +35.56% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
See More
Previous Close:
$16.19
Open:
$16.4
24h Volume:
2.95M
Relative Volume:
1.36
Market Cap:
$1.47B
Revenue:
$139.71M
Net Income/Loss:
$-209.36M
P/E Ratio:
-5.7568
EPS:
-2.96
Net Cash Flow:
$-160.60M
1W Performance:
+4.35%
1M Performance:
+35.56%
6M Performance:
+17.68%
1Y Performance:
-13.06%
1-Day Range:
$16.29
$17.23
1-Week Range:
$15.81
$17.23
52-Week Range:
$8.58
$22.50
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
17.04 | 1.39B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
Point72 Europe London LLP Acquires Shares of 184,683 Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Wellington Management Group LLP Sells 4,198,493 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Why is Syndax Pharmaceuticals Inc. stock going downEarnings Growth Summary & Weekly Stock Performance Updates - خودرو بانک
Syndax Pharmaceuticals (NASDAQ:SNDX) Coverage Initiated at Guggenheim - MarketBeat
Trexquant Investment LP Trims Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
How does Syndax Pharmaceuticals Inc. perform in inflationary periodsJuly 2025 Levels & Real-Time Stock Price Movement Reports - خودرو بانک
What chart patterns are forming on Syndax Pharmaceuticals Inc.July 2025 Selloffs & Entry Point Confirmation Signals - خودرو بانک
Does Syndax Pharmaceuticals Inc. meet Warren Buffett’s criteriaJuly 2025 News Drivers & Technical Buy Zone Confirmation - خودرو بانک
Can Syndax Pharmaceuticals Inc. deliver consistent dividendsJuly 2025 Recap & Fast Moving Market Watchlists - خودرو بانک
Is Syndax Pharmaceuticals Inc. stock a value trapMarket Trend Report & Risk Controlled Daily Plans - خودرو بانک
Invesco Ltd. Has $944,000 Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | SNDX Stock News - GuruFocus
Syndax Pharmaceuticals' Strategic Use of Inducement Grants to Fuel Long-Term Growth - AInvest
What’s the profit margin of Syndax Pharmaceuticals Inc.2025 EndofYear Setup & Short-Term High Return Strategies - خودرو بانک
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Signal strength of Syndax Pharmaceuticals Inc. stock in tech scannersJuly 2025 Decliners & Weekly High Potential Stock Alerts - Newser
Is a relief rally coming for Syndax Pharmaceuticals Inc. holdersInsider Buying & Real-Time Stock Price Movement Reports - Newser
Should I trade or invest in Syndax Pharmaceuticals Inc.July 2025 Short Interest & Weekly High Return Stock Opportunities - خودرو بانک
Goldman Sachs Raises Price Target on Syndax Pharmaceuticals (SND - GuruFocus
Does Syndax Pharmaceuticals Inc. have consistent dividend growthJuly 2025 Technicals & Risk Adjusted Swing Trade Ideas - خودرو بانک
Can a trend reversal in Syndax Pharmaceuticals Inc. lead to recoveryJuly 2025 Levels & Real-Time Stock Movement Alerts - Newser
Will Syndax Pharmaceuticals Inc. benefit from macro trendsEarnings Miss & Community Verified Trade Signals - Newser
Palo Alto Investors LP Buys 39,174 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Ieq Capital LLC Invests $727,000 in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Will Syndax Pharmaceuticals Inc. continue its uptrendWeekly Trade Report & Weekly Sector Rotation Insights - Newser
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Will Syndax Pharmaceuticals Inc. benefit from green energy policiesMarket Movers & Expert Approved Trade Ideas - خودرو بانک
Guggenheim initiates Syndax Pharmaceuticals stock with Buy rating on AML drug success - Investing.com Canada
Understanding Syndax Pharmaceuticals Inc.’s price movementWeekly Trend Summary & Smart Money Movement Alerts - Newser
Syndax Pharmaceuticals Inc. (SNDX) Gains Attention with Promising Drug Portfolio and Narrower-than-Expected Q2 Loss - AInvest
Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth - Benzinga
Is this a good reentry point in Syndax Pharmaceuticals Inc.2025 Investor Takeaways & Risk Managed Trade Strategies - Newser
Nuveen LLC Acquires Shares of 224,153 Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Real time breakdown of Syndax Pharmaceuticals Inc. stock performanceGlobal Markets & Long-Term Safe Investment Plans - Newser
Predicting Syndax Pharmaceuticals Inc. trend using moving averagesJuly 2025 Selloffs & Free Real-Time Volume Trigger Notifications - Newser
What are the future prospects of Syndax Pharmaceuticals Inc.2025 Trading Recap & Daily Oversold Stock Bounce Ideas - خودرو بانک
Can trapped investors hope for a rebound in Syndax Pharmaceuticals Inc.Quarterly Profit Summary & Long-Term Capital Growth Ideas - Newser
Tema Etfs LLC Buys Shares of 21,169 Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
How high can Syndax Pharmaceuticals Inc. stock price go in 2025Market Growth Review & Consistent Profit Trading Strategies - Newser
Syndax Pharmaceuticals Inc. recovery potential after sell offEarnings Growth Report & Trade Opportunity Analysis Reports - Newser
Russell Investments Group Ltd. Has $1.45 Million Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Statistical indicators supporting Syndax Pharmaceuticals Inc.’s strengthProfit Target & Accurate Intraday Trading Signals - Newser
Smart tools for monitoring Syndax Pharmaceuticals Inc.’s price actionPortfolio Return Report & Precise Trade Entry Recommendations - Newser
Intraday pattern recognizer results for Syndax Pharmaceuticals IncPrice Action & Real-Time Volume Trigger Notifications - Newser
Syndax Pharmaceuticals' Strategic Position in the Evolving Oncology Landscape - AInvest
Is Syndax Pharmaceuticals Inc. still a buy after recent gainsEarnings Overview Summary & Smart Investment Allocation Tips - خودرو بانک
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):